infectious disease

RECENT POSTS

Zika Virus Prompts ‘Global Emergency,’ So Why Don’t U.S. Officials Sound Worried?

A doctor draws blood from Luana, who was born with microcephaly, at the Oswaldo Cruz Hospital in Recife, Brazil. Brazilian officials believe there's a sharp increase in cases of microcephaly and strongly suspect the Zika virus, which first appeared in the country last year, is to blame. (Felipe Dana/AP)

A doctor draws blood from Luana, who was born with microcephaly, at the Oswaldo Cruz Hospital in Recife, Brazil. Brazilian officials believe there’s a sharp increase in cases of microcephaly and strongly suspect the Zika virus, which first appeared in the country last year, is to blame. (Felipe Dana/AP)

By Richard Knox

The World Health Organization on Monday declared a “Public Health Emergency of International Concern” because of a fast-moving outbreak of serious birth defects and some cases of adult paralysis that appear to be connected to the Zika virus.

WHO Director-General Margaret Chan said the situation represents “an extraordinary event and a public health threat to other parts of the world.” The agency says the previously obscure virus has spread to 25 countries and territories in this hemisphere so far.

The declaration comes before definitive proof that the birth defects and neurological illness, called Guillain-Barre syndrome, are caused by the mosquito-borne virus. But Chan said it would be a mistake to wait until a causative link has been proven — or disproven.

“Can you imagine if we did not do all this work now, and waited until the scientific evidence comes out, then people would say…’Why didn’t you take action? Because the mosquito is ubiquitous,’ ” Chan said.

The WHO declared a similar emergency last year because of Ebola in West Africa — but was heavily criticized for waiting too long in that case.

About 4,000 children have been born in Brazil recently with microcephaly, a stunting of the brain and skull associated with severe cognitive defects — a 20-fold increase over the past year. Of these affected infants, 270 were born to mothers who had confirmed exposure to the virus. Brazilian officials estimate that 4 million people there could be infected with Zika in the coming year.

A declaration of public health emergency allows the WHO to release contingency funds to help affected countries track and count cases, explore the possible viral link, help develop a diagnostic test and possibly a vaccine, and intensify efforts to control the mosquitoes that transmit the Zika virus. The WHO does not recommend restricting travel to affected areas, though the Geneva-based agency reiterated its advice to pregnant women to avoid travel to areas where Zika virus is spreading.

Experts say it could take six to nine months to determine if Zika virus is responsible for the explosive increase in microcephaly and occasional cases of Guillain-Barre syndrome. That’s too long to be certain before next July’s Olympics in Brazil, ground zero of the Zika outbreak.

But increasingly few experts doubt that link. There appears to be no other good explanation why Brazil’s tally of microcephaly cases has ballooned from fewer than 200 in 2014 to more than 4,000 since then, while Zika infections in Brazil soared from zero to 1.5 million.

The rapidly evolving picture is not simple. On one hand, the World Health Organization calls the spread “explosive.” In just a few months, the virus has infiltrated 23 Latin and Central American countries. And there seems every prospect that Zika could become endemic in this hemisphere — that is, that it could be around for years to come.

“Zika is here to stay in the Western Hemisphere,” Michael Osterholm, of the Center for Infectious Disease Research and Policy at the University of Minnesota, wrote in The New York Times this weekend. “It will be part of life for many years to come.” Continue reading

Related:

Sorry, Intriguing Studies Are No Excuse To Skip The Flu Shot This Year

 (Rick Wilson/AP Images for NCOA)

(Rick Wilson/AP for NCOA)

By Alison Bruzek

Warning: You may be tempted to use some of the following information to rationalize skipping your annual flu shot. But in fact, you’re out of luck. The message from public health authorities is absolutely clear: roll up your sleeve (or prepare your nasal passages) and get your flu vaccine.

“Just do it now, would be my advice,” said Dr. Larry Madoff, director of epidemiology and immunization at the Massachusetts Department of Public Health. “There’s always a benefit to getting the flu vaccine.”

Granted, you wouldn’t be entirely crazy for thinking otherwise, thanks to recent headlines like these:

From USA Today last winter: “Flu shots only 23% effective this season.

From CBS News: “Flu vaccine might be less effective in statin users.”

And on the front page of The Boston Globe earlier this month: “Repeated flu shots may lose potency.” (The story came from STAT, the Globe’s new online sibling publication covering medicine and bioscience, which used the headline, “Getting a flu shot every year? More may not be better.”)

The STAT story reports in its third paragraph that public health officials “still believe an annual vaccination is better than skipping the vaccines altogether.” But its primary emphasis is on a “growing body of evidence” that with flu vaccines, “more may not always be better.”

As one mother wrote on Facebook, “[It’s] very upsetting for someone like me, who has had their kids vaccinated every year.”

The message is confusing, even for someone well aware of the recommendation from public health authorities that everyone over six months old should get a flu vaccine unless there’s a medical reason to avoid it. Flu is no joke: It kills thousands, and probably tens of thousands, of Americans a year, the CDC says.

So what to do if you’re still worried?

To begin with, listen to the author of the study, Dr. Edward Belongia, an epidemiologist at the Marshfield Clinic Research Foundation. The STAT story notes he still strongly encourages everyone to get their flu vaccine.

As Dr. Belongia told me about his study: “At this point there really aren’t any implications for the general public.” Rather, it’s a jumping-off point for future research. Furthermore, the study was presented as a poster in October at an infectious diseases conference; it hasn’t yet been through the rigorous peer review required for publication in a scientific journal.

The study itself is intriguing — it concluded that children who had gotten a flu shot in two previous years, for a specific strain of the flu, were more likely to contract that flu than kids who had just been vaccinated for the first time.

But Dr. Madoff at the Massachusetts Department of Public Health said the idea that vaccines may bring diminishing returns isn’t new. In fact, it’s been around since the 1990s. And the bottom line, he said, is that “the return may diminish but there’s always a benefit to getting vaccinated.”

Or as a spokesperson for the CDC said, “This is an interesting new finding and CDC will be looking into it further. For now, the CDC recommendation for vaccination remains unchanged.”
Continue reading

Research Raises Prospect Of Springtime Shot To Protect Against Lyme Disease

lymedisease

“Sign me up!”

That was my first, emphatic reaction to word that University of Massachusetts Medical School researchers are making progress toward a shot that we here in Lyme disease territory could get every spring for months-long protection through high tick season. It would use monoclonal antibodies — medical cruise missiles that can hit the narrowest of targets.

Sadly, the research, though promising, is still only in mice, and it will be years before such a shot could possibly be available in humans. But for those of us eagerly awaiting better protection against Lyme disease — not to mention those of us frustrated by this: Why your dog can get vaccinated against Lyme disease and you can’t — it’s heartening news nonetheless.

I asked for details from UMass Medical School professor Mark Klempner, a longtime Lyme disease researcher and executive vice chancellor of MassBiologics, a non-profit, UMass-affiliated maker of vaccines and other public-health-oriented medicines. His colleague, Dr. Yang Wang, just presented their team’s findings to a major conference on infectious disease in San Diego. His summary:

“For the past two-and-a-half years, MassBiologics has been developing a new approach to prevention of Lyme disease, as part of our overall public health efforts to protect the citizens of Massachusetts and beyond for diseases of interest.

We’ve taken a different approach than the vaccine approach, and what we’ve developed is a human monoclonal antibody that, when present in the blood of a host, will prevent the transmission of the Lyme disease bacteria from the tick to that host.

When the tick bites you, it then drinks in a little bit of your blood, and contained within that blood is the medicine that kills the bacteria right in the gut of the tick.

– Dr. Mark Klempner

I want to emphasize that so far these studies have been done exclusively in animals — so-called preclinical studies — and our future is to move this into clinical studies, which we will hopefully initiate in 2016.

The idea here is based on a couple of precedents. The first is: We know that the previously available [Lyme disease] vaccine worked by inducing many, many different antibodies, only one of which was important in the protection. And similarly, we know that there is a precedent for being able to give a safe and effective monoclonal antibody to young babies in order to prevent them from getting a different infectious disease called Respiratory Syncitial Virus.

So for both precedent and safety reasons, we chose to go after a single monoclonal antibody that would be able to prevent the transmission of Lyme disease during the entire season. The monoclonal antibody idea has additional benefit in that when the vaccine was available, it required three shots over six months to induce immunity, and so you needed to start to take the medicine sometime in the winter in order to be able to protected in the following fall, and there was not a lot of uptake of that.

Dr. Mark Klempner (Courtesy UMMS)

Dr. Mark Klempner (Courtesy UMMS)

So here, one of the advantages is that the antibody, if we give it to you, provides you immediate immunity, as it does in a mouse, and it should last for the entire season by engineering the antibody to have a very, very long half life. And then it would be gone at the end of the season, and the next season you would take the medicine again and it should work again for the entire season.

The overall mechanism of the way the antibody works is quite interesting and unique, and it’s really based on the idea that the way you catch Lyme disease is, obviously, by the bite of the tick, and what happens in the tick when it drinks your blood is that there’a a sudden explosion of the organisms in the intestine of the tick, where they begin to multiply very quickly; they change somewhat and then they invade the tick gut and move to the salivary gland, where, during the feeding process they can then be deposited in your skin, where you get that typical bullseye rash, often.

So here the idea is that if you have the circulating antibody going around when the tick bites you, it then drinks in a little bit of your blood and contained within that blood is the medicine that kills the bacteria right in the gut of the tick and thereby prevents transmission.

When we do these studies in mice, that’s exactly what happens. Continue reading

How Contagious Is That Dinner Party? And How Best To Evade Friends’ Bugs?

(Faruk Ateş/Flickr)

(Faruk Ateş/Flickr)

“This is not a question for an expert on etiquette!” I expostulated. “It’s a question for an Infectious Disease specialist!”

The trigger for that objection: A query to Social Qs, the New York Times etiquette column on “awkward situations.” The writer describes a group of 10 close friends who meet regularly for dinner; one, who is immuno-suppressed, asks that another member who is getting over the flu and still on antibiotics keep 12 feet away and avoid touching anything she may eat. The reader asks: “Shouldn’t one of them have declined the invitation? But which?”

The columnist responds that no, no one needed to bow out, and that this distance-setting arrangement seems a good compromise, adding, “I hope the person with the flu called her doctor to make sure she was no longer contagious — for everyone’s sake.”

Surely you can understand my frustration. Fine, the flu patient could call her doctor, but what about the rest of us, hungry for more general knowledge on contagion for our own social gatherings? Why not answer the obvious questions? Like: Is 12 feet really far enough to avoid flu germs? Are you still contagious when you’re finishing a course of antibiotics?

Oddly, the day after I read that column, a similar situation played out at my house: One friend was getting over a respiratory infection, still coughing, and another friend regretfully said she could not stay and chat at the dining table, for fear of carrying a germ to an immuno-compromised loved one.

That did it. I called CommonHealth’s go-to guy on infectious disease questions of public interest, Dr. Ben Kruskal, chief of infectious diseases at Harvard Vanguard Medical Associates, and shared my annoyance. Actually, he gently corrected me, this is an issue of both medical science and etiquette. Our conversation, lightly edited:

Dr. Kruskal: You need to have the facts and then you can figure out the etiquette in light of them.

First, when it come to infectious disease transmission, we know a fair amount, but there’s a lot that is still argued over. So let’s take flu as a good example. We know that there are multiple mechanisms by which flu is transmitted, or by which you could postulate reasonably that it might be transmitted:

Dr. Ben Kruskal (Courtesy)

Dr. Ben Kruskal (Courtesy)

• Physical contact: You’ve got germs on your hands, you touch somebody else’s hands or face. Or indirect contact — you touch your face, and then touch the doorknob. A few minutes later, someone else touches the doorknob and then their face.

And there are two different mechanisms of airborne transmission:

• Respiratory droplets, which fall to the ground pretty quickly after they leave your mouth and nose. People argue about the distance they can travel — some people say three feet, some say six feet. Six is a very conservative estimate.

• And then there’s what’s called true airborne transmission (technically, droplet nuclei), which is the mechanism by which TB, measles and chicken pox are all transmitted. And that’s the kind that can go much longer distances and can linger in the air for a long time afterward.

So which is flu?

Flu looks like it’s probably mostly droplets, with some contact, and then there’s a lot of debate in the medical literature about whether there’s some component of airborne transmission or not. If it’s there, it’s probably not huge — we’re arguing whether it’s .1 percent or 1 percent or 5 percent, but it’s probably not more than that.

What else should we know? Continue reading

5 Reasons You Should Worry Way More About Flu Than Ebola

(CDC)

(CDC)

By Veronica Thomas
Guest Contributor

A deadly virus is sweeping America, putting nearly 10,000 people in the hospital so far. No, it’s not Ebola. We’re talking about the common seasonal flu that shows up every fall and lingers on until spring.

Every year, 5 to 20 percent of Americans get the flu and, depending on the strain, anywhere from 4,000 to 49,000 people die from the virus or its complications, like pneumonia. And this season’s flu virus is shaping up to be pretty nasty — so nasty that the CDC declared a national flu epidemic at the end of December.

As a graduate student at the Harvard School of Public Health, I’m baffled by this: A couple months ago, I couldn’t step on a subway car or flip through Facebook without being bombarded by panicked comments about Ebola spreading to the U.S. But when it comes to the real and immediate threat of the flu: radio silence.

“Ebola is exotic. It has a very high mortality rate that people are very much aware of. It seems like you can be exposed to it without your control,” says Dr. Alfred DeMaria, medical director for the Bureau of Infectious Disease at the Massachusetts Department of Public Health. “All of those [factors] contribute to a higher perception of risk than the flu.”

In reality, far, far more people die from flu-related complications than from Ebola, but it’s a very small proportion of the millions who get sick each year. That’s one reason we should be more concerned about the flu than Ebola, Dr. DeMaria says. Here’s why else:

1) The flu is next door, not across the Atlantic.

Ebola has tragically claimed over 8,600 lives in West Africa, largely because many countries don’t have the capacity to contain the outbreak or treat infected patients. And though the news cycles have moved on, Ebola hasn’t. As the virus continues to spread, Ebola remains a real threat for some West African countries.

But for ordinary Americans: “The risk of getting Ebola is somewhere in the order of magnitude of getting personally hit by a meteorite,” Dr. DeMaria says. Just four people have been treated for Ebola in the U.S., and only one has died. No new cases have been reported since October. Continue reading

Quick, Take Tamiflu? Maybe Not A Slamdunk If You’re Young And Healthy

(Photo via Compfight.com)

(Photo via Compfight.com)

As I listened to CDC director Dr. Tom Frieden issue a ringing endorsement of the prescription antiviral drug Tamiflu last week, I was also hearing a confused “But…but….but…” in my own head.

The crux of my confusion: I had the decided impression that the data on Tamiflu as a flu-fighter were underwhelming. That it just isn’t all that effective. That doctors prescribe it because they have nothing better, but without a lot of hope that it will do a lot of good.

Among the factors that formed that impression:

• A MedPage Today post last month headlined “Why Is Tamiflu Still Around?” with the subhead, “Tamiflu doesn’t help, so why are docs still prescribing it?”

• The data-driven doctors who run the Slow Medicine series had written last week that they accepted the updated CDC guidelines recommending quick antiviral therapy for high-risk patients. But….

“…as for patients who were previously healthy with less severe disease, we are more skeptical. The CDC recommends consideration of antivirals among such patients if the medications can be started within 48 hours of symptom onset. However, we suspect the side effects of antiviral medications are greater than the pharmaceutical companies have let on (identification of adverse effects for short term medications is particularly difficult). In most cases, good supportive care with close follow up will be more helpful than a marginally effective medication with uncertain side effects with attendant risks of future resistance.”

• And Dr. Ben Kruskal, chief of infectious diseases at Harvard Vanguard Medical Associates, had recently responded to my email query about Tamiflu with this:

“My enthusiasm about antivirals for flu is mixed. They’re the best tool we have, but the evidence for the most hoped-for benefits is scanty indeed.”

Bottom line? Dr. Frieden’s bottom line was simply that antivirals are under-used and if a member of his family got the flu, he’d want them treated with Tamiflu. But the chief of the CDC has to think at the level of a whole population; what about those of us who think at the level of an individual?

You may prefer a more nuanced take from the likes of the Slow Medicine analysts and Dr. Kruskal, to wit:

Maybe the real Tamiflu bottom line here is that there’s no simple bottom line.

Yes, if the patient is elderly or a baby or severely ill or otherwise at high risk of flu complications for any number of underlying health conditions — asthma, diabetes, cancer — quick prescription of antivirals (Tamiflu, Relenza and a new intravenous form, peramavir) makes sense. The potential dangers of flu complications in such high-risk patients are especially scary, so the potential benefits from the antivirals loom larger.

But if the patient is otherwise healthy, Dr. Kruskal says, while it’s a reasonable decision to take Tamiflu, “I wouldn’t call it entirely a slam-dunk.” Continue reading

In Tough Flu Year, CDC Touts Prompt Tamiflu Prescriptions

(Photo via Compfight.com)

(Photo via Compfight.com)

Note: We’ve also posted a follow-up to this news story: Quick, Take Tamiflu? Maybe Not A Slamdunk If You’re Young and Healthy.

Flu seasons are never good, but this year’s is shaping up as a notably nasty one. It’s dominated by a strain of virus — known as H3N2 — that tends to cause more severe symptoms and is a poor match for this year’s vaccine. And we’re still right in the middle of it.

So today, CDC director Dr. Tom Frieden issued this new, Tamiflu-touting message to reporters and the public: “Anti-viral flu medications are greatly under-utilized. But if you get the flu, and if you get medicines early, they could keep you out of the hospital; they could keep you from having to go into the intensive care unit; and they might even save your life.”

If I or one of the members of my family got flu or a flu-like illness, I would get them or me treated with Tamiflu as quickly as possible.

– CDC director Dr. Tom Frieden

That message is especially important, he says, for people at high risk for complications of flu, including elders over 65, pregnant women, very young children and people with underlying health issues such as asthma or diabetes. The anti-virals work best if taken within the first 48 hours of flu onset.

In case you’re now feeling an urge to run out and stock up on Tamiflu, well, first of all, you can’t. Tamiflu and its ilk are available only by prescription.

And second, you shouldn’t. It would make you a bad citizen. Frieden reports that though manufacturers have a big enough supply overall, there are spot shortages of Tamiflu around the country, and it may already take some calling around to find a pharmacy with a supply. Stockpiling could deprive patients who need the drug more than you do.

Dr. Alfred DeMaria, medical director for the Bureau of Infectious Disease at the Massachusetts Department of Public Health, says a local pediatrician recently told him about prescribing an antiviral drug for a Cystic Fibrosis patient at high risk for flu complications. The family had to go to several pharmacies before they could fill the prescription.

“Why was that? The pharmacies have just-in-time inventory for expected sales,” Dr. DeMaria says, “and if those expected sales go up because people say, ‘Oh, it’s going to be a bad flu season; they’re recommending Tamiflu; I’m going to get some and keep it just in case,'” then supplies run short.

The new CDC recommendations encouraging health care staffers to write more antiviral prescriptions may surprise those familiar with less-than-exciting reports on how effective the drugs can be. In general, if taken early, they appear to cut the flu’s duration by 20 percent, from an average of five days to four. Continue reading

Reality Check: How People Catch Ebola, And How They Don’t

Dr. Elke Muhlberger (Courtesy of Kalman Zabarsky for BU Photography)

Dr. Elke Muhlberger (Courtesy of Kalman Zabarsky for BU Photography)

It’s confusing. You hear that Ebola victim Thomas Eric Duncan was so contagious that two Dallas nurses in protective gear caught the virus. But then you hear, in more recent days, that apparently nobody else did, including the inner circle who lived with him and cared for him. The CDC announced today that all of Mr. Duncan’s “community contacts” have completed their 21-day monitoring period without developing Ebola.

How to understand that? And how to address alarmists’ claims that for the nurses and so many West Africans to have caught Ebola, it must have gone “airborne”?

I turned to Dr. Elke Muhlberger, an Ebola expert long intimate with the virus — through more than 20 years of Ebola research that included two pregnancies. (I must say I find this the ultimate antidote for the fear generated by the nurses’ infections: A researcher so confident in the power of taking the right precautions that she had no fear — and rightly so, it turned out — for her babies-to-be.)

Dr. Muhlberger is an associate professor of micriobiology at Boston University and director of the Biomolecule Production Core at the National Emerging Infectious Diseases Laboratories (widely referred to as the NEIDL, pronounced “needle”) at Boston University. Our conversation, lightly edited:

Is it really true you worked on Ebola through two pregnancies?

Yes, but in the proper protective gear. That makes a huge difference, if you’re protected, if you know how to protect yourself, and that is the case in a Biosafety Level 4 lab, of course. If you compare the protective gear we’re wearing in a Biosafety Level 4 lab and the gear they’re wearing in West Africa now treating patients, it’s like comparing a stainless steel vault to a cardboard box.

But on the other hand, if you look at the nurses in Dallas, you say, ‘How did they get infected?’ It makes you worry that maybe protective gear isn’t good enough — but you’re proof of the opposite.

A Biosafety Level 4 lab is such a high-end lab, it is not possible to use protective gear like that in every hospital in the U.S.

Could you please lay out a brief primer on the biology of how Ebola is transmitted?

We know from previous outbreaks, and also from the current outbreak, that Ebola is transmitted by having very close contact to infected patients. So we know that it is transmitted by bodily fluids, which include blood, first of all — because the amount of virus in the blood is very, very high, especially at late stages of infection — but it’s also spread by vomit, by sputum, by feces, by urine and by other bodily fluids.

The reason for that is that at late stages of infection, the Ebola virus affects almost all our organs — it causes a systemic infection. One main organ targeted by Ebola virus is the liver, and that could be one of the reasons that we see these very high concentrations of viral particles in the blood. But I would like to emphasize that that occurs late in infection.

Early infection is the other way around. The primary targets — the first cells that come in contact with Ebola virus and get infected — are cells that are part of our immune system. And these cells most likely spread the virus throughout our body. But there are not so many cells infected at the very beginning of the infection, which might be the reason why Ebola virus patients do not spread virus at the very beginning of infection. And that’s why it’s safe to have contact with these patients, because the viral titers in their blood are so low that we cannot even detect them with methods like PCR, which is one of the methods we use to diagnose Ebola virus.

Is a virus only contagious when it reaches a certain level of “titer” or load? Continue reading

Harvard Poll On Ebola Risk Finds Public Dazed And Very Confused

A World Health Organization worker trains nurses on how to use Ebola protective gear in Freetown, Sierra Leone. (AP)

A World Health Organization worker trains nurses on how to use Ebola protective gear in Freetown, Sierra Leone. (AP)

By Richard Knox

Americans are seriously confused about how Ebola spreads. And it’s no wonder.

A new national poll from the Harvard School of Public Health finds that nearly 9 out of 10 Americans think someone can catch Ebola if an infected person sneezes or coughs on them.

Not so, according to all health authorities and 38 years of research on this virus. But maybe people can’t be blamed for thinking Ebola can be spread through the air as they see powerful images day after day of health workers clad in head-to-toe protective coverings and face masks.

And there’s little to no possibility that Ebola will mutate into a virus easily spread by aerosol droplets, like influenza or SARS, for reasons that Laurie Garrett of the Council on Foreign Relations recently pointed out in The Washington Post.

Similarly, all the attention on the imported Ebola case of a Liberian man in Dallas and subsequent infection of two of his nurses (so far) is apparently leading many Americans to overestimate their risk of getting the virus.

In contrast, the great majority (80 percent) think they’d survive Ebola if they got immediate care. That’s probably right — though no sure thing.

(Courtesy of Harvard School of Public Health)

(Courtesy of Harvard School of Public Health)

The Harvard poll, conducted between last Wednesday and Sunday, finds that a little over half of Americans worry there will be a large outbreak of Ebola in this country over the coming year.

More than a third worry they or someone in their immediate family will get Ebola. Continue reading

Curb Your Hysteria: Talking Rationally To Kids About Ebola Risk

A man diagnosed with Ebola this week is being treated at Texas Health Presbyterian Hospital in Dallas. (AP)

A man diagnosed with Ebola this week is being treated at Texas Health Presbyterian Hospital in Dallas. (AP)

By Gene Beresin, MD and Steve Schlozman, MD

On Sept. 30 the first case of Ebola was diagnosed in the United States. The patient, who is currently being treated in Dallas, had recently traveled to Liberia, and was back in this country for a few days before symptoms began.

Understandably, the coverage of this news is pervasive. Although it seemed inevitable that a case in the U.S. would eventually emerge, the story still ignites a fair bit of hand-wringing among just about everyone who has learned of it.

Additionally, our country has experienced some novel infections that have ignited increased concerns in recent weeks. Enterovirus D-68 has made its way across the nation, causing severe cold-like symptoms, and, in some children with conditions such as asthma, the need for hospitalization. There’s also a potentially new contagion on the horizon that appears to cause varying degrees of muscular paralysis, and may or may not be related to Enterovirus D-68.

But, as public health officials are eager to stress, a nuanced and thoughtful approach to these issues has been as necessary as it has been fleeting. Experts agree that our medical infrastructure is well-equipped to handle even a virus as scary as Ebola, and some doctors are quick to point out that viruses like respiratory syncytial virus (RSV) and influenza are much more likely to cause harm than these new ones.

This raises a critical point:

Ebola, as scary as it is, poses a relatively minor threat to the United States; and the current cases of Enterovirus D-68 are far out-numbered by the RSV and influenza cases we experience on a yearly basis. And the currently unknown contagion that appears to cause paralysis has only happened in a very small population of kids.

So why the massive reaction in the media and among worried parents? Intellectually, at least at this point, all indications point to little danger for our children and ourselves. Why, then, do we get so frightened?

Well, let’s start with this confession: We’re frightened.

Sort of.

We know, intellectually, that the threat is minor. But, when has intellect played a leading role in the emotionally driven process of threat assessment? And, especially with regard to infectious disease, when has anyone other than the most statistically driven scientists been able to preserve perspective? We’re not saying that we should massively worry, or even that we’ll be changing our instructions to our kids or our patients on how to behave with these new bugs dancing around.

What we’re saying is that germs, especially new germs, are scary. We have a long and probably evolutionarily derived tendency to fear disease, and when new ones rear their heads, we get alarmed.

Germs In Hollywood

As a society, we think about germs a lot — and nowhere, perhaps, does that play out more than in Hollywood. The 1954 novella “I am Legend” has been made into no less than three movies (“The Last Man on Earth,” “The Omega Man” and the more recent movie of the same title as the written work). You can rattle off other movies as well — there’s “Dawn of the Dead” (in 1978 and again in 2004), “Outbreak,” “Carriers,” “Contagion,” “The Crazies” (in 1973 and again in 2010),

“Quarantine” (and “Quarantine 2”) and most recently “World War Z.” You get the picture. Continue reading